85 related articles for article (PubMed ID: 7830117)
1. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity.
Clerc J; Dagousset F; Izembart M; Jais JP; Heshmati HM; Alcaïs A; Chevalier A; Léger AF; Barritault L
J Nucl Med; 1995 Feb; 36(2):217-23. PubMed ID: 7830117
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
Listewnik MH
Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity.
Als C; Rösler H; Kinser JA
J Nucl Med; 1996 Feb; 37(2):401-3. PubMed ID: 8667087
[No Abstract] [Full Text] [Related]
5. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule.
Matheoud R; Canzi C; Reschini E; Zito F; Voltini F; Gerundini P
Med Phys; 2003 May; 30(5):791-8. PubMed ID: 12772986
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy.
Reschini E; Matheoud R; Canzi C; Castellani M; Galelli M; Ferrari C; Paracchi A; Gerundini P
J Nucl Med; 1999 Nov; 40(11):1928-34. PubMed ID: 10565791
[TBL] [Abstract][Full Text] [Related]
8. An analytical model for improving absorbed dose calculation accuracy in non spherical autonomous functioning thyroid nodule.
Amato E; Lizio D; Ruggeri RM; Raniolo M; Campennì A; Baldari S
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):560-6. PubMed ID: 21242948
[TBL] [Abstract][Full Text] [Related]
9. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
[TBL] [Abstract][Full Text] [Related]
10. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule.
Zakavi SR; Mousavi Z; Davachi B
Nucl Med Commun; 2009 Feb; 30(2):169-75. PubMed ID: 19194214
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine.
Huysmans DA; Corstens FH; Kloppenborg PW
J Nucl Med; 1991 Jan; 32(1):27-30. PubMed ID: 1988632
[TBL] [Abstract][Full Text] [Related]
13. [Changes in thyroid volume after radioactive iodine therapy in patients with single toxic thyroid nodule].
Gołkowski F; Jabrocka-Hybel A; Huszno B
Przegl Lek; 2005; 62(5):284-6. PubMed ID: 16334533
[TBL] [Abstract][Full Text] [Related]
14. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
[TBL] [Abstract][Full Text] [Related]
15. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.
Clerc J; Izembart M; Dagousset F; Jaïs JP; Heshmati HM; Chevalier A; Léger AF; Barritault L
J Nucl Med; 1993 Mar; 34(3):387-93. PubMed ID: 8441028
[TBL] [Abstract][Full Text] [Related]
16. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
17. Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy.
Yano Y; Sugino K; Akaishi J; Uruno T; Okuwa K; Shibuya H; Kitagawa W; Nagahama M; Ito K; Ito K
Ann Nucl Med; 2011 Dec; 25(10):749-54. PubMed ID: 21971604
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
19. [131I-treatment of the autonomous toxic nodule. Assessment of a fixed dose protocol].
Abós MD; Banzo J; Razola P; García F; Prats E
Rev Esp Med Nucl; 1999 Dec; 18(6):431-5. PubMed ID: 10611569
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount.
Schiavo M; Bagnara MC; Pomposelli E; Altrinetti V; Calamia I; Camerieri L; Giusti M; Pesce G; Reitano C; Bagnasco M; Caputo M
Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):301-7. PubMed ID: 23486350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
